On June 2, 2025, Barclays analyst Andrew Mok released an update on CVS Health (CVS, Financial), maintaining the stock's rating at "Overweight." This reflects sustained confidence in the company's potential despite adjustments in price expectations.
The price target for CVS Health was adjusted to $79.00 USD from a previous target of $82.00 USD, indicating a downward revision of approximately 3.66%. The update suggests some recalibration in the stock's expected performance, yet maintains a positive outlook with the "Overweight" rating.
CVS Health (CVS, Financial) continues to be a closely monitored entity in the stock market, with analysts like Andrew Mok keeping a keen eye on its trajectory amidst evolving market conditions. Investors and market enthusiasts will be watching how these developments impact the company's market performance in the coming months.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CVS Health Corp (CVS, Financial) is $78.68 with a high estimate of $95.00 and a low estimate of $70.00. The average target implies an upside of 24.51% from the current price of $63.19. More detailed estimate data can be found on the CVS Health Corp (CVS) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CVS Health Corp's (CVS, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CVS Health Corp (CVS, Financial) in one year is $85.23, suggesting a upside of 34.88% from the current price of $63.19. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CVS Health Corp (CVS) Summary page.
